NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, News, & Analysis

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its earnings results on Monday, May, 6th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.03. The firm had revenue of $0.38 million for the quarter, compared to analysts' expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 107.48% and a negative net margin of 4,539.55%. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Syndax Pharmaceuticals.

7 analysts have issued 12 month price objectives for Syndax Pharmaceuticals' shares. Their predictions range from $5.00 to $26.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $15.6667 in the next twelve months. This suggests a possible upside of 73.5% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.

News coverage about SNDX stock has been trending somewhat positive on Wednesday, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Syndax Pharmaceuticals.

Syndax Pharmaceuticals saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 646,200 shares, an increase of 10.3% from the April 30th total of 585,600 shares. Based on an average daily trading volume, of 188,200 shares, the days-to-cover ratio is presently 3.4 days. Currently, 3.3% of the shares of the stock are short sold. View Syndax Pharmaceuticals' Current Options Chain.

Some companies that are related to Syndax Pharmaceuticals include ZIOPHARM Oncology (ZIOP), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), ArQule (ARQL), Theravance Biopharma (TBPH), ANI Pharmaceuticals (ANIP), Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Omeros (OMER), Deciphera Pharmaceuticals (DCPH), Homology Medicines (FIXX), Axsome Therapeutics (AXSM) and Retrophin (RTRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), TherapeuticsMD (TXMD), Idera Pharmaceuticals (IDRA), Verastem (VSTM), Cara Therapeutics (CARA), Progenics Pharmaceuticals (PGNX), Proteostasis Therapeutics (PTI), Micron Technology (MU) and Synergy Pharmaceuticals (SGYP).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.04%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.

SNDX stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison and Michael L Meyers. View Insider Buying and Selling for Syndax Pharmaceuticals.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $9.03.

Syndax Pharmaceuticals has a market capitalization of $244.68 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.

The official website for Syndax Pharmaceuticals is http://www.syndax.com/.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]